MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Pharmacotherapy"

  • 2025 International Congress

    Positive Relationship Between Improvement in Sleep and Quality of Life During Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion

    R. Hauser, A. Videnovic, P. Odin, K. Chaudhuri, M. Shah, J. Homola, L. Bergmann, R. Gupta, O. Vaou (Tampa, USA)

    Objective: To investigate the relationship between improvements in sleep disturbances and quality of life (QoL) in adults with advanced Parkinson’s disease (aPD) treated with a…
  • 2025 International Congress

    Design of ORCHESTRA Study: Practical Experiences With Foslevodopa/Foscarbidopa Treatment in Advanced Parkinson’s Disease

    A. Johansson, E. Pekkonen, L. Dorresteijn, P. Schwingenschuh, J. Szász, L. Bergmann, M. O'Meara, J. Parra, M. Südmeyer (Helsinki, Finland)

    Objective: To describe the practical management of foslevodopa/foscarbidopa (LDp/CDp) for treating advanced Parkinson’s disease (aPD) in routine clinical practice using data collected through a patient…
  • 2025 International Congress

    Dosage Optimization and Treatment Outcomes of Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson’s Disease: a single center study

    K. Kakuda, Y. Kimura, K. Ikenaka, H. Mochizuki (Suita, Japan)

    Objective: To optimize the dosage of foslevodopa/foscarbidopa continuous subcutaneous infusion (CSCI) therapy for Parkinson’s disease by identifying dosage differences between the continuation and discontinuation groups.…
  • 2025 International Congress

    The Effect of Foslevodopa/Foscarbidopa Treatment on Nonmotor Symptom Burden in Advanced Parkinson’s Disease

    I. Malaty, P. Odin, D. Kern, L. Bergmann, M. Shah, R. Gupta, A. Antonini, K. Chaudhuri (Gainesvile, USA)

    Objective: To investigate the impact of foslevodopa/foscarbidopa (LDp/CDp) on nonmotor symptoms (NMS) in adults with advanced Parkinson’s disease (aPD). Background: LDp/CDp, a 24-hour per day…
  • 2025 International Congress

    Multidimensional Assessment of Levodopa/Carbidopa/Entacapone Gel (LECIG) Therapy in Parkinson’s Disease: Perspectives of Patients, Clinicians, and Caregivers

    M. Minar, I. Straka, Z. Andre, M. Grofik, J. Necpal, M. Rusinkova, V. Han, Z. Kosutzka (Bratislava, Slovakia)

    Objective: To evaluate the impact of Levodopa/Entacapone/Carbidopa Gel (LECIG) therapy on Parkinson’s disease (PD) patients, their caregivers, and clinicians over six months. Background: Advanced PD…
  • 2025 International Congress

    Risk factors for central nervous system side effects of amantadine

    M. Nagai, N. Miyaue, Y. Ito, Y. Yamanishi, R. Ando, Y. Ihara (Ehime, Japan)

    Objective: The purpose of this study was to investigate the threshold blood level of amantadine and risk factors for central nervous system (CNS) side effects…
  • 2025 International Congress

    Tremor in Multifocal Motor Neuropathy

    M. Qurbonova (Dushanbe, Tajikistan)

    Objective: Study of the effect of tremor on the quality of life of patients with multifocal motor neuropathy and its dynamics in response to therapy…
  • 2025 International Congress

    Medication therapy in Parkinson’s disease patients: a cross-sectional study at the University Medical Center at Ho Chi Minh City, Vietnam

    T. Dang, T. Tran (HO CHI MINH, Viet Nam)

    Objective: To determine the rate of drugs prescribed to treat Parkinson's disease motor symptoms, the rate of the types of drug combinations, and the frequency…
  • 2025 International Congress

    Enhancing Safety and Quality of Care for Parkinson’s Disease Patients Hospitalized at a Large Academic Medical Center

    C. Kim, C. Malatt, E. Hogg, E. Tan, M. Tagliati (Los Angeles, USA)

    Objective: To implement measures to improve quality of care in Parkinson's disease (PD) patients who are hospitalized at a large academic hospital with the goal…
  • 2025 International Congress

    Medication Error Reduction Strategies in an In-patient Multimodal Intensive Neurorehabilitation and Care (i-MINC) Program

    N. Yousefzadeh, L. Hom, A. Defrank, M. Mccrossin, L. Rubin (Glen Cove, USA)

    Objective: To evaluate medication safety strategies implemented to reduce medication errors in an i-MINC Program Background: Medication mismanagement may lead to critical patient harm in…
  • 1
  • 2
  • 3
  • …
  • 34
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • #28953 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • VIT-D and Tics Movement Disorder
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley